Viridian Therapeutics reported second quarter 2026 financial results on August 6, 2026, posting a net loss of $127.1 million compared to $100.7 million in the prior year period. The company completed a convertible debt and equity financing in May 2026 with gross proceeds of $394 million, resulting in cash, cash equivalents, and marketable securities of $981.5 million as of June 30, 2026. Research and development expenses decreased to $71.6 million from $86.6 million, while selling, general and administrative expenses increased to $55.0 million due to commercial infrastructure build-out for Lumvoa. The U.S. Food and Drug Administration approved Lumvoa for thyroid eye disease on June 26, 2026, ahead of the PDUFA date, with immediate launch activities underway including physician engagement with 95% of core prescribing physicians by July 31, 2026. The company remains on track to submit a Biologics License Application for elegrobart in Q1 2027 and an Investigational New Drug application for its TSHR program in Q4 2026. Viridian Therapeutics is a biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases.

On June 26, 2026, Viridian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED) regardless of activity or duration. Lumvoa is the first approved treatment for TED with labeling that includes data for both active and chronic TED. Viridian plans to launch Lumvoa immediately. Viridian Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for ophthalmology and immunology.